Immix Biopharma, Inc.
IMMX evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $908.5M
- Lead Asset:
- nxc-201 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for IMMX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMMX
Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharmaceutical company developing sterically-optimized CAR-T cell therapy NXC-201 for AL Amyloidosis and other serious diseases, with a fully enrolled Phase 2 registrational trial and a planned BLA submission in mid-2027.
Key risk: Single-product dependency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$908.5M
Cash Runway
—
Lead Asset
nxc-201 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Immix Biopharma, Inc..
Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharmaceutical company developing sterically-optimized CAR-T cell therapy NXC-201 for AL Amyloidosis and other serious diseases, with a fully enrolled Phase 2 registrational trial and a planned BLA submission in mid-2027.
- Lead candidate NXC-201 is a sterically-optimized CAR-T being evaluated in the fully enrolled, 45-patient U.S. Phase 2 NEXICART-2 trial for relapsed/refractory AL Amyloidosis [sec · filed 2026-09-29].
- As of August 4, 2026, the trial reported a CR rate of up to 98% (44/45) with no relapses observed in patients who achieved CR or MRD-negativity, and no neurotoxicity or enterocolitis observed [sec · filed 2026-09-29].
- Cash & equivalents were $225.5M as of 2026-06-30, with net income of -$11.6M and shareholders' equity of $228.9M [sec].
- The NEXICART-2 final readout and BLA submission are planned for mid-2027 [sec · filed 2026-09-29].
- A multi-center, randomized Phase 3 trial of NXC-201 in newly diagnosed AL Amyloidosis is planned to begin in the first half of 2027 [sec · filed 2026-05-21].
What works
- NXC-201 has shown a high CR rate (up to 98%) with no relapses observed in patients achieving CR or MRD-negativity, and no neurotoxicity or enterocolitis reported [sec · filed 2026-09-29].
- The company has a substantial cash position of $225.5M as of 2026-06-30, providing runway through key milestones including BLA submission [sec].
- NEXICART-2 is designed as a registrational trial, potentially enabling a direct path to BLA approval if results are positive [sec · filed 2026-09-29].
What to weigh
- The company has incurred recurring losses, with a net loss of -$11.6M for the period ending 2026-06-30, and has stated that the majority of losses are attributable to research and development [sec_mda · as of 2026-08-07].
- The company is heavily dependent on the success of a single lead candidate, NXC-201, with other programs still in preclinical or early stages [sec_mda · as of 2026-08-07].
- The BLA submission is not planned until mid-2027, meaning there is a long period before potential revenue generation, and regulatory approval is not guaranteed [sec · filed 2026-09-29].
From the filings
Quoted directly from source documents.
High CR rate and no relapses observed
“increasing future CR rate up to 98% (44/45). No relapses have been observed to date for patients who reached CR or MRD-negativity.”
SEC filings · September 29, 2026
No neurotoxicity or enterocolitis observed
“No neurotoxicity or enterocolitis has been observed to date.”
SEC filings · September 29, 2026
BLA submission planned for mid-2027
“The NEXICART-2 final readout and BLA submission are planned in mid-2027.”
SEC filings · September 29, 2026
Catalyst timeline
- 2026-09-30 · Phase 2 Topline Readout for NXC-201 — Expected Phase 2 topline data readout for NXC-201 in relapsed/refractory AL Amyloidosis; company guidance indicated results expected in Q3 2026.
Risks & what to watch (3)›
Key risks
- Single-product dependency — Company's pipeline is heavily reliant on NXC-201; other programs are preclinical or early stage [sec_mda · as of 2026-08-07].
- Regulatory and clinical uncertainty — BLA submission not until mid-2027; no guarantee of approval or commercial success [sec · filed 2026-09-29].
- Recurring net losses — Net loss of -$11.6M as of 2026-06-30, with R&D expenses driving losses [sec].
What to watch
- NEXICART-2 final readout and BLA submission planned for mid-2027 [sec · filed 2026-09-29].
- Initiation of a multi-center, randomized Phase 3 trial for newly diagnosed AL Amyloidosis in first half of 2027 [sec · filed 2026-05-21].
- Cash runway and burn rate given $225.5M cash as of 2026-06-30 and ongoing net losses [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Immix Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immix Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.04 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$242.1M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 4,802,002 | $43.7M |
| saturn v capital management lp | 3,693,585 | $33.6M |
| eventide asset management, llc | 2,549,019 | $23.2M |
| vanguard capital management llc | 1,787,994 | $16.3M |
| millennium management llc | 1,750,200 | $15.9M |
| marshall wace, llp | 1,641,552 | $15.0M |
| logos global management lp | 1,225,000 | $11.2M |
| bleichroeder lp | 1,000,000 | $9.1M |
| franklin resources inc | 969,066 | $8.8M |
| velan capital investment management lp | 740,000 | $6.7M |
Showing top 10 of 77 institutional holders of Immix Biopharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 7.7%
- Days to cover
- 3.6
- Shares short
- 3,115,947
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMMX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Immix Biopharma, Inc.?
Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharmaceutical company developing sterically-optimized CAR-T cell therapy NXC-201 for AL Amyloidosis and other serious diseases, with a fully enrolled Phase 2 registrational trial and a planned BLA submission in mid-2027.
What is Immix Biopharma, Inc.'s lead drug candidate?
Immix Biopharma, Inc.'s most advanced tracked candidate is nxc-201 (Phase 1) for Relapsed/refractory multiple myeloma and relapsed/refractory light chain (AL) amyloidosis.
Who is the CEO of Immix Biopharma, Inc.?
Dr. Ilya Rachman M.B.A., M.D., Ph.D. is the chief executive officer of Immix Biopharma, Inc. (IMMX).
Where is Immix Biopharma, Inc. headquartered?
Immix Biopharma, Inc. (IMMX) is headquartered in Los Angeles, CA, United States.
What therapeutic areas does Immix Biopharma, Inc. focus on?
Immix Biopharma, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.